Iclusig for mastocytosis – pto
M. Vae writes (citation below): “Ponatinib, another multikinase inhibitor, has shown activity on KITV560G and, less effectively, on KITD816V in the human mast cell leukemia cell line human mast cell line-1 (HMC-1) (67, 68). Ponatinib also synergizes with midostaurin to obtain growth inhibition against neoplastic mast cells harboring the KITD816V mutant. However, clinical trials are needed to assess the in vivo efficacy of ponatinib, alone or in combination.” Arock et al expresses the same sentiment.
Mhatterjee A, Ghosh J, Kapur R. Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder. Oncotarget. 2015 Jul 30;6(21):18250-64.
Mm Vae et al, Targeted Treatment Options in Mastocytosis. Front. Med., 19 July 2017
Sec. Hematology Volume 4 – 2017
M Arock et al, Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. E J Hematology Volume94, Issue6 June 2015 Pages 474-490